Cellceutix Reports its Novel Anti-Cancer Agent, Kevetrin, at Dana-Farber for Start of Clinical Trials

BEVERLY, MA–(Marketwire – Aug 6, 2012) – Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company focused on discovering small molecule drugs for hard to treat diseases, announced today that Kevetrin™, the Company’s flagship anti-cancer drug, has been received at the pharmacies at Dana-Farber Cancer Institute for the commencement of clinical trials. Further, Cellceutix is also pleased to report that the trial details are expected to be viewable on the www.clinicaltrials.gov website this week.

“To date, everything is completed and we are waiting for the host hospitals to begin dosing patients, which we anticipate will happen shortly, but it is in the hospitals’ hands at this point,” commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. ”Throughout my career, I have evaluated and seen many new drug candidates go from start to finish through the regulatory pathway and I am extremely optimistic and excited about the potential of Kevetrin™ because of our data collected during extensive studies and the p53 connection as the Mechanism of Action. I’m not aware of any other anti-cancer compound at this stage of development that could have such a dramatic impact in the field of oncology. Dana-Farber is one of the few hospitals in the world that collects data ‘mapping’ the human genome as related to tumor profiling and the information that will be collected from our clinical trials of Kevetrin™ could prove an invaluable asset to those suffering from cancer and to Cellceutix.”

On a side note, Cellceutix would like to congratulate the men’s U.S. Olympic basketball team as well as Cellceutix Advisor, Dream Team 2 Assistant Coach Jim Boeheim, on its record-setting performance last Wednesday and wishes the team continued success in their quest for the gold medal.

To learn more about Kevetrin™ and the potent anti-cancer activity that it has demonstrated across multiple cancer lines, please visit our website.